H. Cheng

A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

Y. An, Haifeng Song, Jie Lv, 2018, BioDrugs.